View in browser

“Just like I called the start of the gold run in 2022, I’m telling you now: biotech takeovers are about to mint millionaires.”

Karim Rahemtulla, Head Fundamental Tactician, Monument Traders Alliance 

Dear Reader,

There’s a pattern I’ve learned to recognize over the years. It starts with whispers. Quiet accumulation. Money moving before the crowd notices.

Back in 2022… I started telling my readers to get into gold and precious metals.

Here’s what I saw…

Central banks around the world were buying bullion. The biggest kahuna of them all, the U.S., was piling on debt.

Those two factors alone were enough to ignite more buying ahead.

Fast-forward to 2026… I nailed it. Gold topped $4,635 an ounce (up 72% year over year), silver hit $92 an ounce (up 200% in a year) – validating those early signals.

Now I’m telling you to buy stocks in the biotech sector.

Here’s why…

Big pharma is sitting on a patent cliff that’s about to become a revenue catastrophe.

Between 2026 and 2030, the sector faces a “super-cliff” with $180 billion to $236 billion in annual revenue at risk from patent expirations.

I’m talking about blockbusters like Merck’s Keytruda ($25 billion in annual sales), expiring in 2028… Pfizer’s Ibrance ($6.4 billion), going off patent in 2027… and dozens more.

They have to replace that revenue – and fast. That urgency is driving an M&A explosion.

SPONSORED

Log Into Keith’s $5,000 Website

A website that shows you the biggest potential jumps on 5,000 stocks – to the day – weeks before they occur.

Last year alone, you could have doubled your money 13 times with our official recommendations.

Until Jan. 20, you can claim free access here.

Biotech M&A exploded 73% to $228 billion in 2025 – and analysts predict more than 20 deals over $1 billion each in 2026.

Just look at what happened with obesity drugmaker Metsera last year.

When Pfizer and Novo Nordisk got into a bidding war over the company, Metsera’s shares doubled as the price escalated from initial bids of $4.9 billion to Pfizer’s winning $10 billion offer.

Or take Revolution Medicines(RVMD), which jumped 29% on Merck takeover rumors, pushing its market cap near $20 billion.

These aren’t small moves. This is a sector where triple-digit gains are the norm during takeovers.

In the War Room, we’ve already cleaned up twice in the past two years on State Street SPDR S&P Biotech ETF (XBI), which surged 36% in 2025 alone.

But that’s not where the big money will be made.

The big money will come from individual stocks that no one is looking at… no one but big pharma.

And that is where I have my focus in the War Room and in Catalyst Cash-Outs Live.

It’s a sector ripe with opportunities.

YOUR ACTION PLAN

Two under-$10 stocks are on my radar now… and one of them is under $5.

Both have huge potential as standalone companies or takeover targets.

A third stock is a biotech play that uses AI to develop drugs.

That’s just three out of many opportunities in this sector.

These plays are still relatively unknown to most people, but not to Big Pharma.

They’re arguably the most knowledgeable about which companies have potential and which don’t.

And they have the deep pockets to make multiple bets. With $1.2 trillion in acquisition capacity burning a hole in their balance sheets and pipelines that desperately need replenishing, they’re ready to write big checks.

The data backs up what I’m seeing. There were 129 deals worth $138 billion in biopharma alone last year, with the October-November period seeing a $36 billion surge.

The feeding frenzy is just getting started.

Don’t miss this like the crowd missed gold at $1,800. The biotech takeover wave is here.

And if you want to know what I’m playing, check out Catalyst Cash-Outs Live.

---

FUN FACT FRIDAY

In 1886, Atlanta pharmacist John Pemberton created “Coca-Cola” as a brain tonic and headache remedy, mixing coca leaf extract (with about 9 mg of cocaine per glass initially) and kola nut extract (containing caffeine).

He sold it at soda fountains for ailments like morphine addiction, indigestion, and nerve issues. It was marketed as a “valuable brain tonic” before becoming the world’s most iconic soft drink.

---

INSIGHTS YOU MAY HAVE MISSED

How Long Can This Silver Run Last?

Inside the Amazon Decision That Lost Millions

How “Nested Squeezes” Can Lead to Huge Gains (Three 100% Winners)

Fed Investigation Creates Trading Gold Rush

SPONSORED

496% Overnight… 1,129% in 2 Days…
And 2,100% in Only 24 Hours
(Want Unlimited Access Every System Behind These Wins?)

Monument Traders Alliance has delivered (an average) of 1,130 winning trade recommendations in the last 12 months.

Returns of 496% overnight… 1,129% in 2 days… even 2,100% in 24 hours.

Now, imagine having unlimited access to EVERY service that generated those wins.

That’s what Bryan Bottarelli is offering to just 300 people. And it’s called “The Inner Circle Partnership”.

It allows you unlimited access to every trade recommendation, AI tool, service, and trading chat room we offer…

Plus, private invitations to luxury trading retreats across the globe.Click Here to Get the Details

Monument Traders Alliance, LLC

You are receiving this email because you subscribed to Trade of the Day.
To unsubscribe from Trade of the Day, click here.

Questions? Check out our FAQs. Trying to reach us? Contact us here.
Please do not reply to this email as it goes to an unmonitored inbox.

To cancel by mail or for any other subscription issues, write us at:
Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201

North America: 800.507.1399 | International: +1.443.353.4977
Website | Privacy Policy
Keep the emails you value from falling into your spam folder. Whitelist Trade of the Day.

© 2026 Monument Traders Alliance, LLC | All Rights Reserved

Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation.

Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.

REF: 000142349377